Browsing Over 32 Presentations

Sort By
Interaction between CDKs, CDKI and other targets (ID 6) Educational session

PIK3 (ID 19)

Lecture Time
09:40 - 10:00
Speakers
  • Violeta Serra (Barcelona, ES)
Session Name
Interaction between CDKs, CDKI and other targets (ID 6)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
09:00 - 10:50
Preclinical evidence of efficacy (ID 5) Educational session

Preclinical evidence of activity of abemaciclib (ID 14)

Lecture Time
17:20 - 17:40
Speakers
  • Maria Lallena (Alcobendas, ES)
Session Name
Preclinical evidence of efficacy (ID 5)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
16:40 - 18:10
The concept of CDK inhibition according to the targeted CDK subtype (ID 4) Educational session

CDK 4-6 inhibition (ID 9)

Lecture Time
14:30 - 14:50
Speakers
  • Monica Arnedos (Villejuif, FR)
Session Name
The concept of CDK inhibition according to the targeted CDK subtype (ID 4)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
14:30 - 16:20
The role of CDK along the mitotic process in normal and pathological condition (ID 3) Educational session

Integration of multiple signalling pathways through control of CDK activation (ID 2)

Lecture Time
13:20 - 13:40
Speakers
  • Luca Malorni (Prato, IT)
Session Name
The role of CDK along the mitotic process in normal and pathological condition (ID 3)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
13:20 - 14:30
CDK4 and CDK6 inhibitors in breast cancer (ID 8) Educational session

Q&A (ID 32)

Lecture Time
14:50 - 15:00
Session Name
CDK4 and CDK6 inhibitors in breast cancer (ID 8)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
13:30 - 15:00
The disappointing results of initial CDKI and their role in other disease (ID 7) Educational session

CDKi in non-malignant diseases (ID 27)

Lecture Time
12:00 - 12:25
Speakers
  • Laurent Meijer (Roscoff, FR)
Session Name
The disappointing results of initial CDKI and their role in other disease (ID 7)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
11:10 - 12:40
Interaction between CDKs, CDKI and other targets (ID 6) Educational session

Interaction with immune system (ID 21)

Lecture Time
10:20 - 10:40
Speakers
  • Fabrice AndrĂ© (Villejuif, FR)
Session Name
Interaction between CDKs, CDKI and other targets (ID 6)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
09:00 - 10:50
Preclinical evidence of efficacy (ID 5) Educational session

Q&A (ID 16)

Lecture Time
18:00 - 18:10
Session Name
Preclinical evidence of efficacy (ID 5)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
16:40 - 18:10
The concept of CDK inhibition according to the targeted CDK subtype (ID 4) Educational session

Q&A (ID 11)

Lecture Time
16:10 - 16:20
Session Name
The concept of CDK inhibition according to the targeted CDK subtype (ID 4)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
14:30 - 16:20
The role of CDK along the mitotic process in normal and pathological condition (ID 3) Educational session

Q&A (ID 6)

Lecture Time
14:00 - 14:10
Session Name
The role of CDK along the mitotic process in normal and pathological condition (ID 3)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
13:20 - 14:30
Welcome and introduction (ID 1) Educational session

Welcome to the Symposium (ID 34)

Lecture Time
11:30 - 11:45
Speakers
  • Alberto Bardelli (Candiolo, IT)
  • Josep Tabernero (Barcelona, ES)
Session Name
Welcome and introduction (ID 1)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
11:30 - 11:45
CDK4 and CDK6 inhibitors in breast cancer (ID 8) Educational session

Ribociclib (ID 29)

Lecture Time
13:50 - 14:10
Speakers
  • Fabrice AndrĂ© (Villejuif, FR)
Session Name
CDK4 and CDK6 inhibitors in breast cancer (ID 8)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
13:30 - 15:00